Global Active Pharmaceutical Ingredient Market Outlook to 2027
Active pharmaceutical ingredients are a combination of substances used in finished pharmaceutical products. These substances are intended to furnish pharmacological activity or to have a direct effect on the cure, diagnosis, mitigation, treatment, or prevention of diseases. According to MarketStack Reports, the global market for the active pharmaceutical ingredient is expected to grow at a considerable rate during the forecast period 2021-2025.
Factors driving the market include the increasing occurrence of chronic diseases and increasing consumption of generics. Ongoing advancements in the manufacturing of active pharmaceutical ingredients are also driving the market. However, market growth is being restricted by high manufacturing costs.The global pharmaceutical market is anticipated to grow at around 4% (despite the COVID-19 pandemic) during the forecast period. The ongoing pandemic has decreased the growth rate from 5% to 4%.In 2019, the global pharmaceutical market valued around USD 1,223.4 billion, and the North American pharmaceutical market accounted for about 49% of the revenue share.In 2019, the global sales from exported drugs and medicines value at USD 392.9 billion, an increase of 3.2% compared to 2018. Europe accounted for about 80% of the total global exports with shipments valued at USD 317.1 billion.Major countries in the export of drugs and medicines include Germany, Switzerland, the Netherlands, Belgium, France, Italy, the United States, United Kingdom, Ireland, and Denmark among others. The top 10 countries account for about 75% of total exports.However, with the restrictions on the movements of goods and public coupled with the halted operations of the manufacturing facilities during the imposed lockdowns, the pharmaceutical industry faced sluggish supply issues (the majority of pharmaceutical industry key ingredients are supplied by China). This trend of inconsistent supply is also expected to promote the domestic production of key ingredients for several countries with abundant raw materials.
In terms of geography, North America was found to be the major region for the global active pharmaceutical ingredient market. The market in the region is being driven by the increasing focus of government generic drugs coupled with the technological advancements in the APIs manufacturing processes.
•The United States is the world's largest economy. The country's GDP has decreased at an annual rate of 5% in the first quarter and 9.5% in the second quarter of 2020 due to the ongoing coronavirus pandemic. However, the economy expanded by an annualized 33.1% in Q3 2020.Globally, the United States is the single largest market for pharmaceutical products. However, it lags behind other nations in terms of API production for drugs marketed in the country.Currently, around 28% of the manufacturing facilities involved in the production of APIs for the United States are based in the country and the remaining facilities are located outside the US.As a part of shifting the pharmaceutical production offshore, in the recent decade, the API production in the country has shifted to China. The reliance on the consistent supply of APIs into the country has increased.The overall economic impact of the pharmaceutical industry on the U.S. economy is substantial. The industry accounts for more than USD 2 trillion in economic output, representing nearly 5% of the total U.S. output. Moreover, the United States attracts the majority of global venture capital investments in start-up biopharmaceutical enterprises.By type, branded pharmaceutical products dominated the global market owing to their high prices and exclusivity with certain licensed manufacturers. In terms of synthesis, the synthetic type is likely to dominate the market.
The global market for active pharmaceutical ingredients is led by major players including Lonza, Sanofi, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Novartis AG, and Mylan NV among others.
GlobalActive Pharmaceutical Ingredient Market report provides deep insight into the active pharmaceutical ingredientmarket's current and future state across various regions. The study comprehensively analyzes the active pharmaceutical ingredient market by segmenting based on Drug Type (innovative, Generic), Manufacturer(Captive, Marchant), Type (Diabetes, Oncology, Cardiovascular, Neurology, Anti-Inflammatory,and Others), and Geography (Asia-Pacific, North America, Europe, South America, and Middle-East and Africa). The report examines the market drivers and restraints, along with the impact of Covid-19 on the market growth in detail. The study covers & includes emerging market trends, developments, opportunities, and challenges in the industry. This report also covers extensively researched competitive landscape sections with profiles of major companies, including their market shares and projects.
Factors driving the market include the increasing occurrence of chronic diseases and increasing consumption of generics. Ongoing advancements in the manufacturing of active pharmaceutical ingredients are also driving the market. However, market growth is being restricted by high manufacturing costs.The global pharmaceutical market is anticipated to grow at around 4% (despite the COVID-19 pandemic) during the forecast period. The ongoing pandemic has decreased the growth rate from 5% to 4%.In 2019, the global pharmaceutical market valued around USD 1,223.4 billion, and the North American pharmaceutical market accounted for about 49% of the revenue share.In 2019, the global sales from exported drugs and medicines value at USD 392.9 billion, an increase of 3.2% compared to 2018. Europe accounted for about 80% of the total global exports with shipments valued at USD 317.1 billion.Major countries in the export of drugs and medicines include Germany, Switzerland, the Netherlands, Belgium, France, Italy, the United States, United Kingdom, Ireland, and Denmark among others. The top 10 countries account for about 75% of total exports.However, with the restrictions on the movements of goods and public coupled with the halted operations of the manufacturing facilities during the imposed lockdowns, the pharmaceutical industry faced sluggish supply issues (the majority of pharmaceutical industry key ingredients are supplied by China). This trend of inconsistent supply is also expected to promote the domestic production of key ingredients for several countries with abundant raw materials.
In terms of geography, North America was found to be the major region for the global active pharmaceutical ingredient market. The market in the region is being driven by the increasing focus of government generic drugs coupled with the technological advancements in the APIs manufacturing processes.
•The United States is the world's largest economy. The country's GDP has decreased at an annual rate of 5% in the first quarter and 9.5% in the second quarter of 2020 due to the ongoing coronavirus pandemic. However, the economy expanded by an annualized 33.1% in Q3 2020.Globally, the United States is the single largest market for pharmaceutical products. However, it lags behind other nations in terms of API production for drugs marketed in the country.Currently, around 28% of the manufacturing facilities involved in the production of APIs for the United States are based in the country and the remaining facilities are located outside the US.As a part of shifting the pharmaceutical production offshore, in the recent decade, the API production in the country has shifted to China. The reliance on the consistent supply of APIs into the country has increased.The overall economic impact of the pharmaceutical industry on the U.S. economy is substantial. The industry accounts for more than USD 2 trillion in economic output, representing nearly 5% of the total U.S. output. Moreover, the United States attracts the majority of global venture capital investments in start-up biopharmaceutical enterprises.By type, branded pharmaceutical products dominated the global market owing to their high prices and exclusivity with certain licensed manufacturers. In terms of synthesis, the synthetic type is likely to dominate the market.
The global market for active pharmaceutical ingredients is led by major players including Lonza, Sanofi, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Novartis AG, and Mylan NV among others.
GlobalActive Pharmaceutical Ingredient Market report provides deep insight into the active pharmaceutical ingredientmarket's current and future state across various regions. The study comprehensively analyzes the active pharmaceutical ingredient market by segmenting based on Drug Type (innovative, Generic), Manufacturer(Captive, Marchant), Type (Diabetes, Oncology, Cardiovascular, Neurology, Anti-Inflammatory,and Others), and Geography (Asia-Pacific, North America, Europe, South America, and Middle-East and Africa). The report examines the market drivers and restraints, along with the impact of Covid-19 on the market growth in detail. The study covers & includes emerging market trends, developments, opportunities, and challenges in the industry. This report also covers extensively researched competitive landscape sections with profiles of major companies, including their market shares and projects.
1. Executive Summary
2. Research Scope and Methodology
2.1 Aim & Objective of the study
2.2 Market Definition
2.3 Study Information
2.4 General Study Assumptions
2.5 Research Phases
3. Market Analysis
3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.2 Restraints
3.3 Market Trends & Developments
3.4 Market Opportunities
3.5 Feedstock Analysis
3.6 Regulatory Policies
3.7 Analysis of Covid-19 Impact
4. Industry Analysis
4.1 Supply Chain Analysis
4.2 Porter's Five Forces Analysis
4.2.1 Competition in the Industry
4.2.2 Potential of New Entrants into the Industry
4.2.3 Bargaining Power of Suppliers
4.2.4 Bargaining Power of Consumers
4.2.5 Threat of substitute products
5. Market Segmentation & Forecast
5.1 By Drug Type
5.1.1 Innovative
5.1.2 Generic
5.2 By Manufacturer
5.2.1 Captive
5.2.2 Merchant
5.3 By Type
5.3.1 Biological
5.3.2 Chemical
5.4 By Application
5.4.1 Cardiovascular Drugs
5.4.2 Diabetic Drugs
5.4.3 Oncology Drugs
5.4.4 Neurology Drugs
5.4.5 Anti-inflammatory Drugs
5.4.6 Others
6. Regional Market Analysis
6.1 North America
6.1.1 United States
6.1.2 Canada
6.1.3 Mexico
6.2 Europe
6.2.1 Germany
6.2.2 United Kingdom
6.2.3 Italy
6.2.4 France
6.2.5 Russian Federation
6.2.6 Nordic Countries
6.2.7 Rest of Europe
6.3 Asia-Pacific
6.3.1 China
6.3.2 India
6.3.3 Japan
6.3.4 South Korea
6.3.5 Rest of Asia-Pacific
6.4 South America
6.4.1 Brazil
6.4.2 Argentina
6.4.3 Rest of South America
6.5 Middle East & Africa
6.5.1 South Africa
6.5.2 Saudi Arabia
6.5.3 Rest of Middle East & Africa
7. Key Company Profiles
7.1 AbbVie
7.2 Astrazeneca
7.3 Aurobindo Pharma
7.4 BASF SE
7.5 Boehringer Ingelheim GmbH
7.6 Dr. Reddy's Laboratories Ltd
7.7 Eli Lilly and Company
7.8 F. Hoffmann-La Roche AG
7.9 GlaxoSmithKline Plc
7.10 Lonza
7.11 Lupin Ltd
7.12 Mylan NV
7.13 Novartis AG
7.14 Pfizer Inc.
7.15 Sanofi
7.16 Sun Pharmaceutical Industries Ltd
7.17 Teva Pharmaceutical Industries Ltd
8. Competitive Landscape
8.1 List of Notable Players in the Market
8.2 M&A, JV, and Agreements
8.3 Market Share Analysis
8.4 Strategies of Key Players
9. Conclusions and Recommendations
2. Research Scope and Methodology
2.1 Aim & Objective of the study
2.2 Market Definition
2.3 Study Information
2.4 General Study Assumptions
2.5 Research Phases
3. Market Analysis
3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.2 Restraints
3.3 Market Trends & Developments
3.4 Market Opportunities
3.5 Feedstock Analysis
3.6 Regulatory Policies
3.7 Analysis of Covid-19 Impact
4. Industry Analysis
4.1 Supply Chain Analysis
4.2 Porter's Five Forces Analysis
4.2.1 Competition in the Industry
4.2.2 Potential of New Entrants into the Industry
4.2.3 Bargaining Power of Suppliers
4.2.4 Bargaining Power of Consumers
4.2.5 Threat of substitute products
5. Market Segmentation & Forecast
5.1 By Drug Type
5.1.1 Innovative
5.1.2 Generic
5.2 By Manufacturer
5.2.1 Captive
5.2.2 Merchant
5.3 By Type
5.3.1 Biological
5.3.2 Chemical
5.4 By Application
5.4.1 Cardiovascular Drugs
5.4.2 Diabetic Drugs
5.4.3 Oncology Drugs
5.4.4 Neurology Drugs
5.4.5 Anti-inflammatory Drugs
5.4.6 Others
6. Regional Market Analysis
6.1 North America
6.1.1 United States
6.1.2 Canada
6.1.3 Mexico
6.2 Europe
6.2.1 Germany
6.2.2 United Kingdom
6.2.3 Italy
6.2.4 France
6.2.5 Russian Federation
6.2.6 Nordic Countries
6.2.7 Rest of Europe
6.3 Asia-Pacific
6.3.1 China
6.3.2 India
6.3.3 Japan
6.3.4 South Korea
6.3.5 Rest of Asia-Pacific
6.4 South America
6.4.1 Brazil
6.4.2 Argentina
6.4.3 Rest of South America
6.5 Middle East & Africa
6.5.1 South Africa
6.5.2 Saudi Arabia
6.5.3 Rest of Middle East & Africa
7. Key Company Profiles
7.1 AbbVie
7.2 Astrazeneca
7.3 Aurobindo Pharma
7.4 BASF SE
7.5 Boehringer Ingelheim GmbH
7.6 Dr. Reddy's Laboratories Ltd
7.7 Eli Lilly and Company
7.8 F. Hoffmann-La Roche AG
7.9 GlaxoSmithKline Plc
7.10 Lonza
7.11 Lupin Ltd
7.12 Mylan NV
7.13 Novartis AG
7.14 Pfizer Inc.
7.15 Sanofi
7.16 Sun Pharmaceutical Industries Ltd
7.17 Teva Pharmaceutical Industries Ltd
*List of companies is not exhaustive
8. Competitive Landscape
8.1 List of Notable Players in the Market
8.2 M&A, JV, and Agreements
8.3 Market Share Analysis
8.4 Strategies of Key Players
9. Conclusions and Recommendations
